Dr Katrin Rupalla’s arrival was announced as 4D also said non-executive director David Norwood would be retiring from the board at the end of the month after six years with the drug developer.
Rupalla is currently head of regulatory affairs, medical documentation and R&D quality at Lundbeck, the Danish drug group. She has also held senior positions at Roche, Celgene and Bristol-Myers Squibb.
In a statement, 4D’s chief executive Duncan Peyton said: "We are delighted to be able to attract someone of Katrin's calibre to our board of directors. Her vast experience guiding novel therapies through the clinic will be invaluable as we progress our pipeline of novel Live Biotherapeutics into and through the clinic.
“With her background so well aligned with 4D's core focus areas of oncology and CNS, Katrin's experience and network across Europe, the US and China will support 4D's growth as we continue to expand our global profile."
Working in the emerging area of the human microbiome (the bacteria that reside mainly in the gut), 4D has developed Live Biotherapeutics — products that contain live organisms such as human commensal bacteria.
Toxicity has always been a major impediment to the success of new drugs.
In developing its Live Biotherapeutics, 4D has isolated bacteria from healthy human donors which are expected to have “highly attractive safety profiles”.